AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
AngioDynamics (ANGO) Reports In-Line Q4 EPS, Revenues Miss
July 16, 2020 7:02 AM EDTAngioDynamics (NASDAQ: ANGO) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $58.3 million versus the consensus estimate of $64.3 million.
Fiscal 2020 Fourth Quarter Highlights
Net sales of $58.3 million decreased 18.1% compared to the prior-year quarterGross margin declined 630 basis points year over year to 51.8%GAAP loss per share of $4.10, inclusive of approximately $4.14 of goodwill impairment; adjusted loss per share of $0.06Cash and... More